Navigation Links
BGI develops RNA-Seq (Quantification) from as low as 100 Ng total RNA
Date:9/20/2011

September 20th, 2011,Shenzhen, China BGI, the world's largest genomics organization, reported that they have achieved optimization RNA-Seq (Quantification) library construction with total RNA inputs as low as 100 ng. This breakthrough enables the application of RNA-Seq (Quantification) technology to experimental designs utilizing samples derived from small numbers of cells, such as those widely used in pharmaceutical research, cancer research, and immunology.

RNA-Seq (Quantification), a version of Next Generation Sequencing (NGS), is used for transcriptome quantification and analyzing the gene expression of certain biological objects in specific conditions. It can be widely applied in biomarker detection, basic medical research, drug discovery, among others. Compared with microarray technology, high-throughput RNA sequencing can provide comprehensive assessment of RNA expression profiles with the advantages of high-throughput data, low background, high sensitivity and repeatability.

However, some tissues or cultures from specialized cells involved in clinical and pharmaceutical research make it difficult to obtain sufficient RNA for RNA-Seq (Quantification), which previously required 1 μg or more total RNA. BGI has optimized the procedures to enable RNA-Seq (Quantification) using as little as 100 ng total RNA sample input to generate high-quality data. "The improvement of RNA-Seq (Quantification) not only can simplify sample preparation, but also make this sequencing service more cost-effective and with rapid turnaround time," said Jiong Zhang, Technical Specialist at BGI.

To ensure the accuracy and quality of data, many evaluations have been conducted at BGI, including the reads quality, assessments of reads randomness, gene coverage, experimental reproducibility, and data accuracy. Results demonstrated that the data generated from 100 ng sample input library was as high-quality as that from traditional 1 μg RNA input library. "I hope our enhanced technique can contribute more to drug discovery and therapeutic application in the future," added Zhang.


'/>"/>

Contact: Liu Jia
liujia@genomics.cn
Beijing Genomics Institute
Source:Eurekalert

Related biology news :

1. UConn scientist develops sterile variety of invasive plant
2. BGI develops new strategy to uncover structural variations of human genomes
3. How muscle develops: A dance of cellular skeletons
4. New research provides insight into how OCD develops
5. UBC-led team develops platform to monitor hematopoietic stem cells
6. NJIT professor develops a biologically inspired catalyst, an active yet inert material
7. NC State develops material to remove radioactive contaminants from drinking water
8. Advertising Research Foundation Develops Standards for Neuromarketing Research
9. Syracuse University team develops functionally graded shape memory polymers
10. WebLib develops application for Elseviers SciVerse applications
11. Researcher develops accurate method for detecting dangerous fluoride
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or ... its major shareholders, Clean Technology Fund I, LP and ... based venture capital funds which together hold ... a fully diluted, as converted basis), that they have ... entire equity holdings in Biorem to TUS Holdings Co. ...
(Date:6/27/2016)... ... 2016 , ... Parallel 6 , the leading software as a service ... Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine communication ... , Using the CONSULT module, patients and physicians can schedule a face to face ...
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
Breaking Biology Technology: